| Formulary Chapter 6: Endocrine system - Full Chapter
|
| Chapter Links... |
 SE London APC Blood Glucose Control Management Pathway for Adults with Type 2 Diabetes Mellitus (T2DM) |
| Details... |
| 06.06.02 |
Bisphosphonates and other drugs affecting bone metabolism |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 06.06.02 |
Bisphosphonates |
|
|
Alendronic acid tabs
|
First Choice
|
 FIRST-LINE ORAL BISPHOSPHONATE
|
|
|
Disodium etidronate tabs
|
Formulary
|
|
|
|
Disodium pamidronate injection
|
Formulary
|
Approved for licensed use, and the following off-label indication:
Non-malignant hypercalcaemia - follow local guidelines
|
 MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
|
Ibandronic acid injection
|
 Restricted
|
CONSULTANT SPECIALISTS ONLY
Treatment of osteoporosis in postmenopausal women at increased risk of fracture, who do not tolerate oral bisphosphonates
|
MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
|
Risedronate tabs
|
Formulary
|
|
|
|
Risedronate, calcium carbonate and colecalciferol tabs
|
Formulary
|
|
|
|
Sodium clodronate caps, tabs
|
Formulary
|
|
|
|
Zoledronic acid injection 4mg
|
Restricted
|
RESTICTED USE – ONCOLOGY, HAEMATOLOGY & UROLOGY ONLY
|
MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
|
Zoledronic acid injection 5mg
|
Restricted
|
CONSULTANT SPECIALISTS ONLY
Paget’s disease of the bone
Osteoporosis in post-menopausal women and men at increased risk of fracture
Treatment of osteoporosis associated with long-term systemic glucocorticoid therapy in post-menopausal women and in men at increased risk of fracture
|
MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
|
Zoledronic acid injection 4mg
|
Restricted
|
 Approved off-label indication:
Improved outcomes in early stage post-menopausal breast cancer
Dose = 4mg infusion every 6 months after completion of adjuvant chemotherapy - maximum 5 years treatment
Consultant oncologists only
|
MHRA Jul 2015: Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk
|
| 06.06.02 |
Denosumab |
|
|
| 06.06.02 |
Strontium renelate |
|
|
| .... |
Key |
|
|
|
|
Cytotoxic Drug
|
|
|
Controlled Drug
|
|
High Cost Medicine
|
|
Cancer Drugs Fund
|
|
NHS England |
|
Homecare |
|
CCG |
|
Traffic Light Status Information
| Status |
Description |
|
Specialist or hospital prescribing only.
The responsibility for prescribing, monitoring, dose adjustment and review should remain with the specialist or hospital.
In very exceptional circumstances a specialist may discuss individual patient need for a RED drug to be prescribed by a GP and the GP should consider informing the Medicines Management team before a decision is made to prescribe for individual patients.
|
|
Treatment can be initiated in primary care after a recommendation from an appropriate specialist |
|
Specialist initiation followed by maintenance prescribing in primary care |
|
Specialist initiation with ongoing monitoring required. After dose stabilisation GPs can be requested to take over prescribing responsibilities using the approved APC shared care documentation |
|
Specialist and non-specialist initiation |
|
Not recommended for prescribing |
|
|
|
